The DOI matches its Crossref record; 93 of the 97 references it cites were found in a registry or an index.
Management of multiple myeloma: a systematic review and critical appraisal of published studies
Abstract
We have done a systematic review of all randomised studies in myeloma, identified through a comprehensive search. Our aim was to investigate and critically examine the effects of various treatment modalities on outcome in patients with multiple myeloma and address 22 specific clinical questions in the management of this disease. As a result of our analysis we identified two therapeutic advances in the management of myeloma that, according to the evidence, are most important for improving outcome. These advances were: introduction of high dose chemotherapy, which appears to be superior to conventional chemotherapy, and the use of bisphosphonates, which decrease the probability of pathological vertebral fractures. However, the overall quality of the body of evidence for myeloma management was poor. Many trials were done with small sample sizes, and did not include reporting power analysis. The majority of studies had inadequate allocation concealment, and few were analysed according to intention to treat principle. We conclude that the quality of total evidence supporting treatment recommendations in myeloma is modest at best and has an ample scope for improvement.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [128]
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,401
Research works printed but not linked: 10
- Djulbegovic, 2002, Database for health outcomes and quality of randomized trials in multiple myeloma, Proc Am Soc Clin Oncol, 21, 251a
- Lenhard, 1994, Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma, Cancer, 73, 2113, 10.1002/1097-0142(19940415)73:8<2113::AID-CNCR2820730816>3.0.CO;2-3 · doi:10.1002/1097-0142(19940415)73:8<2113::aid-cncr2820730816>3.0.co;2-3
- Musto, 1999, Intensive chemotherapy followed by single or multiple peripheral blood stem cell transplant (PBSCT) improves the prognosis of patients affected by multiple myeloma (MM) with high proliferative activity, Blood, 94, 576a
- Morgan, 2002, The MRC Myeloma VII trial of standard versus intensive treatment in patients <65 years of age with multiple myeloma, Blood, 100, 178a
- Attal, 2002, Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the “Intergroupe Francophone du Myelome” (IMF 94), Blood, 100, 5a
- Cavo, 2002, The “Bologna 96” clinical trial of single vs. double autotransplant for previously untreated multiple myeloma, Blood, 100, 179a
- Djulbegovic, 2002, Biophosphonates in multiple myeloma, Cochrane Database Systematic Reviews, 3, CD003188
- Heim, 1995, Prospective randomized trial of dichloromethilene bisphosphonate (clodronate) in patients with multiple myeloma, Onkologie, 18, 439
- Garton, 1995, Epoetin alfa for the treatment of the anemia of multiple myeloma, Arch Intern Med, 155, 2069, 10.1001/archinte.1995.00430190059008 · doi:10.1001/archinte.1995.00430190059008
- Kraj, 2000, The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma, Acta Haematologica Polonica, 31, 379
Cited by
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
“Autologous Stem Cell Transplant Autologous stem cell transplant improves complete response rates and prolongs median OS in MM by approximately 12 months.(13,14,74,75) The treatment-related mortality (TRM) rate is 1% to 2%, and the procedure can be performed entirely on an outpatient basis in more than 50% of patients.”
BackgroundMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Metadata
- Authors
- Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B.
- Affiliations
- University of South Florida (US)
- Cedars-Sinai Medical Center (US)
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2003-05
- Volume
- 4
- Issue
- 5
- Pages
- 293-304
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2144719592
- Semantic Scholar
- c855879afa83a6f1b09aeb7ce7abce97944cfcf7
- Cited by
- 113
- References
- 97
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 4
- FWCI
- 1.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- multiple myeloma, high-dose chemotherapy, bisphosphonates, pathological vertebral fractures, treatment outcomes, quality of evidence, allocation concealment, intention-to-treat analysis, randomised trials
- MeSH terms
- Epoetin Alfa, Bortezomib, Antineoplastic Combined Chemotherapy Protocols, Boronic Acids, Diphosphonates, Drug Administration Schedule, Erythropoietin, Hematinics, Humans, Melphalan, Multiple Myeloma, Neoplasm Staging, Pyrazines, Recombinant Proteins, Time Factors, Transplantation, Autologous, Transplantation, Homologous, Survival Analysis, Bone Marrow Transplantation, Randomized Controlled Trials as Topic, Bone Marrow Purging, Salvage Therapy, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of multiple myeloma: a systematic review and critical appraisal of published studies. https://app.cochat.ai/papers/10.1016/s1470-2045(03)01077-5
- The paper
- Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B. (2003). Management of multiple myeloma: a systematic review and critical appraisal of published studies. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(03)01077-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.